LYPD3
LYPD3 Molecule Information
Name:Ly6/PLAUR domain-containing protein 3
Target Synonym:GPI-anchored metastasis-associated protein C4.4A homolog;MIG-C4;Matrigel-induced gene C4 protein;LYPD3;C4.4A
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase ?
LYPD3 Molecule Synonym Name
LYPD3,MIG-C4,C4.4A
LYPD3 Molecule Background
Ly6/PLAUR domain-containing protein 3 (LYPD3) is also known as MIG-C4 ,C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein,which is a cell membrane protein containing two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. LYPD3 is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. LYPD3 play a role in supporting cell migration and it is not only probably involved in urothelial cell-matrix interactions, but also in tumor progression.
LYPD3 References
LYPD3 Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| Lupartumab amadotin |
BAY-1129980,BAY1129980 |
Phase Ⅰ |
Bayer |
Solid tumours |
Details
|
A-Z
